Krystal Biotech, Inc. (KRYS) vs Kymera Therapeutics, Inc. (KYMR)
- Krystal Biotech, Inc. KRYS 316.58 −4.07%
- Kymera Therapeutics, Inc. KYMR 104.78 −3.11%
Krystal Biotech, Inc. and Kymera Therapeutics, Inc. are both Biotechnology companies. Krystal Biotech, Inc. and Kymera Therapeutics, Inc. are of similar size ($9.8B and $9.0B). Kymera Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Krystal Biotech, Inc. trades at 38.3×. Kymera Therapeutics, Inc. grew revenue faster over the last twelve months: 134.8% against 22.6%. Krystal Biotech, Inc. has the higher net margin (54.8% vs −285.3%) and the higher return on invested capital (24.1% vs −26.7%). Across the 17 metrics below, Krystal Biotech, Inc. leads on 13 and Kymera Therapeutics, Inc. on 4.
Valuation
Profitability
| Metric | KRYS | KYMR | Biotechnology median |
|---|---|---|---|
| Gross margin | 94.64% | 100.00% | 65.16% |
| Operating margin | 44.89% | (333.50%) | 0.00% |
| Net margin | 54.82% | (285.33%) | 0.00% |
| Free cash flow margin | 58.52% | (226.62%) | 0.00% |
| Return on equity | 20.12% | (24.15%) | (56.36%) |
| Return on assets | 18.30% | (21.58%) | (48.04%) |
| Return on invested capital | 24.07% | (26.72%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack